January 2026
PTSD
What January 2026's 5 new studies found, synthesized from the papers below. All PTSD research →
The synthesis
Synthesized from 5 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.
Research on PTSD in January 2026 found that a large randomized trial showed no overall benefit of ketamine over placebo, though DNA methylation patterns may predict which individuals respond. Naturalistic survey data indicate that difficult psychedelic experiences can lead to PTSD symptoms in a subset of users, and case reports suggest both potential adverse effects (e.g., new-onset OCD after MDMA-assisted therapy) and possible benefits of oral glutamatergic augmentation. Overall, findings are preliminary and based on small or single studies, with no large-scale definitive results.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Combining DNA methylation features and clinical characteristics predicts ketamine treatment response for PTSD. 2026 | RCT (subgroup analysis with machine learning) | Mixed | Ketamine showed no overall benefit over placebo, but a DNA methylation-based model predicted treatment response with 92.9% accuracy. | |
| Blunted arginine vasopressin secretion in individuals experiencing a major depressive episode with comorbid post-traumatic stress disorder: Results from an exploratory study using copeptin as a surrogate marker. 2026 | observational | Unclear | Participants with MDE+PTSD had lower baseline copeptin levels and blunted post-ketamine copeptin reduction compared to MDE-only, but copeptin was unrelated to symptom severity. | |
| Post-traumatic stress disorder symptoms following psychedelic use: a naturalistic survey study 2026 | observational (survey) | 243 | Supports | 31.3% of participants met DSM-5 criteria for PTSD following a difficult psychedelic experience, with avoidance predicting greater symptoms. |
| Case Report: Oral glutamatergic augmentation for trauma-related disorders with fluoxetine-/bupropion-potentiated dextromethorphan ± piracetam: a four-patient case series. 2026 | case series | 4 | Supports | All four patients showed clinically meaningful symptom improvement within days to weeks on an oral glutamatergic protocol. |
| New‐Onset Obsessive–Compulsive Symptoms After MDMA‐Assisted Psychotherapy in a Patient With Refractory PTSD: A Case Report 2026 | case report | 1 | Opposes | A patient developed new-onset OCD following MDMA-assisted psychotherapy, with symptoms persisting over a year. |
Ketamine showed no overall benefit over placebo, but a DNA methylation-based model predicted treatment response with 92.9% accuracy.
RCT (subgroup analysis with machine learning)
Participants with MDE+PTSD had lower baseline copeptin levels and blunted post-ketamine copeptin reduction compared to MDE-only, but copeptin was unrelated to symptom severity.
observational
31.3% of participants met DSM-5 criteria for PTSD following a difficult psychedelic experience, with avoidance predicting greater symptoms.
observational (survey) Sample size: 243
All four patients showed clinically meaningful symptom improvement within days to weeks on an oral glutamatergic protocol.
case series Sample size: 4
A patient developed new-onset OCD following MDMA-assisted psychotherapy, with symptoms persisting over a year.
case report Sample size: 1
Points of agreement
- Ketamine and related glutamatergic agents are being explored for PTSD, but efficacy may be limited to subgroups.
- Psychedelic and MDMA-assisted therapies carry potential risks, including adverse psychiatric outcomes.
- Biomarker and genetic approaches may help identify treatment responders.
Conflicts
- The large CAP-ketamine trial found no overall benefit of ketamine, while a case series reported rapid improvement with an oral glutamatergic protocol.
- MDMA-assisted therapy is reported as effective in reducing PTSD symptoms in one case, but also linked to new-onset OCD in another.
Gaps
- No large-scale replication of DNA methylation prediction models for ketamine response.
- Durability of treatment effects and long-term outcomes are not addressed.
- Blinding and control conditions are lacking in survey and case studies.
- Populations studied are heterogeneous; no standardized dosing or protocols.
- Mechanisms linking psychedelic experiences to PTSD symptoms are not established.